HAART in HIV/AIDS Treatments: Future Trends

Author(s): Da-Yong Lu*, Hong-Ying Wu, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Ting-Ren Lu.

Journal Name: Infectious Disorders - Drug Targets

Volume 18 , Issue 1 , 2018

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.

Keywords: HAART, antiviral therapy, HIV cure, drug delivery system, medicinal chemistry, HIV latency, HIV reservoirs, integrase inhibitors, pharmacogenomics, biotherapy.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 1
Year: 2018
Page: [15 - 22]
Pages: 8
DOI: 10.2174/1871526517666170505122800

Article Metrics

PDF: 48
HTML: 12
EPUB: 1
PRC: 1